Risks and Management of Metoprolol Discontinuation

High‑Risk Populations

• Abrupt metoprolol withdrawal in patients with coronary artery disease can precipitate severe angina, myocardial infarction, and ventricular arrhythmias – a safety warning emphasized by the FDA label and the ACC/AHA guidelines based on clinical evidence. 1
• Sudden cessation of metoprolol leads to clinical deterioration in patients with heart failure, requiring careful avoidance of abrupt stop‑pacing. (ACC/AHA guideline recommendation) 2

Recommended Discontinuation Protocol

• When metoprolol must be stopped, the dosage should be tapered gradually over 1–2 weeks with close monitoring, as stipulated by the FDA label and endorsed by the ACC/AHA guidelines. (Level of evidence not explicitly graded) 3

Prevention Strategies

• A prolonged low‑dose taper (e.g., 50 mg/day for 10 days) reduces but does not completely eliminate rebound beta‑adrenergic hypersensitivity; gradual tapering is superior to abrupt cessation. (Circulation study) 2

• The magnitude and duration of beta‑blockade–related rebound appear to correlate with drug potency and length of therapy, suggesting that more potent or long‑term regimens may require a slower taper. (Circulation observation) 4